# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k071712   
B. Purpose for Submission: New device   
C. Measurand: Lactoferrin, fecal   
D. Type of Test: Lateral flow immunochromatographic assay   
E. Applicant: TechLab, Inc.   
F. Proprietary and Established Names: TechLab $^ \mathrm { \textregistered }$ LEUKO EZ VUE™   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DEG Lactoferrin,antigen, antiserum,control</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 866.5570Lactoferrinimmunological testsystem</td><td rowspan=1 colspan=1>Immunology 82</td></tr></table>

# H. Intended Use:

1. Intended use(s):

The LEUKO EZ VUE™ test is an immunochromatographic test for the qualitative detection of elevated levels of fecal lactoferrin, a marker for fecal leukocytes and an indicator of intestinal inflammation. The LEUKO EZ VUE™ test detects lactoferrin in liquid, semi-solid, and solid fecal specimens. A positive test result indicates an increased level of fecal lactoferrin and warrants additional testing.

2. Indication(s) for use: Same as Intended Use

3. Special conditions for use statement(s): For prescription use

4. Special instrument requirements: Timer

I. Device Description:

The test kit consists of membrane cassettes, diluent, positive control, disposable plastic pipettes (flared section $= 5 0 \mu \mathrm { L }$ ), and disposable sample preparation devices (tubes and filter tips).

J. Substantial Equivalence Information:

1. Predicate device name(s): a. TechLab $^ \mathrm { \textregistered }$ LEUKO-TEST b. Microscopy using methylene blue or Gram stain – exempt laboratory method

2. Predicate 510(k) number(s):

a. k931241 b. Not applicable

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>TechLab LEUKO EZVUE</td><td rowspan=1 colspan=1>TechLab LEUKO-TEST</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The detection oflactoferrin in fecalspecimens</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analyte measured</td><td rowspan=1 colspan=1>Fecal lactoferrin</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Capture antigen</td><td rowspan=1 colspan=1>Polyclonal rabbit anti-lactoferrin antibodies</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Test matrix</td><td rowspan=1 colspan=1>Stool</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Indications for Use</td><td colspan="1" rowspan="1">An indicator of intestinalinflammation</td><td colspan="1" rowspan="1">Not stated</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Lateral flowimmunochromatography</td><td colspan="1" rowspan="1">Latex agglutination</td></tr><tr><td colspan="1" rowspan="1">Internal (procedural)control</td><td colspan="1" rowspan="1">Stripe containing mouseanti-IgG antibodies</td><td colspan="1" rowspan="1">Not applicable</td></tr><tr><td colspan="1" rowspan="1">Solid phase</td><td colspan="1" rowspan="1">Flow membrane cassette</td><td colspan="1" rowspan="1">Latex particles</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Colloidal gold</td><td colspan="1" rowspan="1">Not applicable</td></tr><tr><td colspan="1" rowspan="1">Result interpretation</td><td colspan="1" rowspan="1">Positive: two red lines arevisible: single red lines atboth the test and thecontrol portions of theResults WindowNegative: no line at thetest portion and a singlered line at the controlportionInvalid: control line is notpresent or if no linesappear on the completedmembrane cassette</td><td colspan="1" rowspan="1">Positive: visible 1+ to 4+agglutinationNegative: no visibleagglutination</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Positive only</td><td colspan="1" rowspan="1">Positive and negative</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">TechLab LEUKO EZVUE</td><td colspan="1" rowspan="1">Laboratory microscopy</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">The detection of</td><td colspan="1" rowspan="1">Detection of leukocytes</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">lactoferrin in fecalspecimens</td><td colspan="1" rowspan="1">in fecal smears</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Lateral flowimmunochromatography</td><td colspan="1" rowspan="1">Manual microscopicobservation of stainedfecal smears to detectleukocytes</td></tr><tr><td colspan="1" rowspan="1">Stain for leukocytedetection andmorphology</td><td colspan="1" rowspan="1">Not applicable</td><td colspan="1" rowspan="1">Methylene blue or Gramstain</td></tr><tr><td colspan="1" rowspan="1">Sample stability for theassay</td><td colspan="1" rowspan="1">Stable when stored asdirected</td><td colspan="1" rowspan="1">Samples must be runwithin minutes as someenteric pathogensproduce toxins that maylyse leukocytes anddegrade lactoferrin</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

“Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests: Draft Guidance for Industry and FDA Reviewers”; CLSI EP7-A, Interference Testing in Clinical Chemistry.

# L. Test Principle:

The membrane cassette contains two stripes of immobilized antibodies. One stripe contains rabbit anti-lactoferrin conjugated directly to gold particles. The other, representing a control stripe, contains mouse anti-IgG antibodies. The diluted sample and gold conjugate migrate by capillary action when the sample is added to the well. If elevated lactoferrin is present in the sample, gold conjugate-lactoferrin complexes form and are captured by the immobilized anti-lactoferrin antibodies in the stripe. The lactoferrin-conjugate-antibody complexes appear as a single read line in the test portion of the Results Window. In the control stripe, conjugate binds to the immobilized anti-IgG antibodies, demonstrating correct migration of the sample and conjugate along the membrane. The conjugate-anti-IgG antibodies appear as a single read line in the control portion of the Results Window.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Intra-assay: Nineteen human fecal specimens were analyzed a total of six times in the same assay run with a single lot of the test. The specimens included 6 samples with values close to the cut-off for positive/negative. For the analysis, a single 1:50 dilution of each fecal specimen was prepared in kit diluent as described in the package insert. All positive specimens remained positive and all negative specimens remained negative. Inter-assay:

Twenty human fecal specimens were analyzed once a day using separate specimen dilutions done fresh each day during a 3-day period using a single lot of the test. The specimens included 6 samples close to the assay cut-off. All positive specimens remained positive and all negative specimens remained negative.

b. Linearity/assay reportable range: Not applicable

TechLab does not claim that any assay components are traceable to a standard reference material. The expiration date of the kit is assigned based on the shortest expiration date of any of the components. Expiration dating was set at 9 months. Stability testing is still being evaluated and may be extended.

d. Detection limit/analytical sensitivity:

The analytical sensitivity was determined using serial twofold dilutions of highly purified human lactoferrin. Dilutions were tested on $3 \mathrm { k i t }$ lots. For all 3 lots, the test was consistently positive at a concentration of $1 2 8 ~ \mathrm { { n g / m L } }$ lactoferrin and negative at a concentration of $6 4 ~ \mathrm { n g / m L }$ .

e. Analytical specificity:

# Cross-reactivity:

Various intestinal organisms were examined for cross-reactivity. For the analysis, broth cultures mixed 1:50 with 1X diluent were evaluated. Broth cultures at log phase containing ${ \geq } 1 0 ^ { 8 }$ bacteria per mL were used. No crossreactivity was observed with any of the following organisms:

<table><tr><td rowspan=1 colspan=1>Acinetobacter lwoffi</td><td rowspan=1 colspan=1>Clostridium novyi (types A,B,C)</td></tr><tr><td rowspan=1 colspan=1>Aeromonas hydrophila</td><td rowspan=1 colspan=1>Clostridium perfringens (types A,B,C,D,E)</td></tr><tr><td rowspan=1 colspan=1>Bacillus cereus</td><td rowspan=1 colspan=1>Clostridium septicum</td></tr><tr><td rowspan=1 colspan=1>Bacillus subtilis</td><td rowspan=1 colspan=1>Clostridium sporogenes</td></tr><tr><td rowspan=1 colspan=1>Bacteroides distasonis</td><td rowspan=1 colspan=1>Clostridium tetani</td></tr><tr><td rowspan=1 colspan=1>Bacteroides eggerthii</td><td rowspan=1 colspan=1>Enterococcus faecalis</td></tr><tr><td rowspan=1 colspan=1>Bacteroides fragilis</td><td rowspan=1 colspan=1>Eubacterium aerofaciens</td></tr><tr><td rowspan=1 colspan=1>Bacteroides ovatus</td><td rowspan=1 colspan=1>Escherichia coli</td></tr><tr><td rowspan=1 colspan=1>Bacteroides stercoris</td><td rowspan=1 colspan=1>Fusobacterium prausnitzii</td></tr><tr><td rowspan=1 colspan=1>Bacteroides thetaiotaomicron</td><td rowspan=1 colspan=1>Klebsiella pneumoniae</td></tr><tr><td rowspan=1 colspan=1>Bacteroides uniformis</td><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td></tr><tr><td rowspan=1 colspan=1>Bacteroides vulgatus</td><td rowspan=1 colspan=1>Pseudomonas vulgaris</td></tr><tr><td rowspan=1 colspan=1>Bifidobacterium adolescent&#x27;s</td><td rowspan=1 colspan=1>Peptostreptococcus anaerobius</td></tr><tr><td rowspan=1 colspan=1>Bifidobacterium longum</td><td rowspan=1 colspan=1>Salmonella choleraesuis</td></tr><tr><td rowspan=1 colspan=1>Campylobacter jejuni</td><td rowspan=1 colspan=1>Salmonella enteritidis</td></tr><tr><td rowspan=1 colspan=1>Candida albicans</td><td rowspan=1 colspan=1>Salmonella typhi</td></tr><tr><td rowspan=1 colspan=1>Candida krusei</td><td rowspan=1 colspan=1>Salmonella typhimurium</td></tr><tr><td rowspan=1 colspan=1>Candida tropicalis</td><td rowspan=1 colspan=1>Shigella dysenteriae</td></tr><tr><td rowspan=1 colspan=1>Clostridium bifermentans</td><td rowspan=1 colspan=1>Shigella flexneri</td></tr><tr><td rowspan=1 colspan=1>Clostridium chauvoei</td><td rowspan=1 colspan=1>Shigella sonnei</td></tr><tr><td rowspan=1 colspan=1>Clostridium difficile</td><td rowspan=1 colspan=1>Staphylococcus aureus</td></tr><tr><td rowspan=1 colspan=1>Clostridium haemolyticum</td><td rowspan=1 colspan=1>Vibrio parahaemolyticus</td></tr><tr><td rowspan=1 colspan=1>Clostridium histolyticum</td><td rowspan=1 colspan=1>Yersinia enterocolitica</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 1 (ATCC #VR-1)</td><td rowspan=1 colspan=1>Coxsackievirus B2 (VR-29)</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 2 (ATCC #VR-846)</td><td rowspan=1 colspan=1>Coxsackievirus B2 (VR-30)</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 3 (ATCC #VR-3)</td><td rowspan=1 colspan=1>Coxsackievirus B2 (VR-184)</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 5 (ATCC #VR-5)</td><td rowspan=1 colspan=1>Coxsackievirus B2 (VR-185)</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 40 (ATCC #VR-931)</td><td rowspan=1 colspan=1>Echovirus 18 (VR-48)</td></tr><tr><td rowspan=1 colspan=1>Human coronavirus (ATCC #VR-740)</td><td rowspan=1 colspan=1>Echovirus 33 (VR-582)</td></tr><tr><td rowspan=1 colspan=1>Enterovirus type 70 (VR-836)</td><td rowspan=1 colspan=1>Enterovirus type 70 (VR-784)</td></tr></table>

# Interfering substances:

Two positive and 2 negative samples were spiked with potentially interfering substances and 7 replicates of each were tested. The substances had no effect on test results when present in feces in the concentrations indicated:

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentration</td></tr><tr><td rowspan=1 colspan=1>Mucin</td><td rowspan=1 colspan=1>5% w/v</td></tr><tr><td rowspan=1 colspan=1>Serum containing lipid (fecal fats)</td><td rowspan=1 colspan=1>5% v/v</td></tr><tr><td rowspan=1 colspan=1>Mylanta®</td><td rowspan=1 colspan=1>5% v/v</td></tr><tr><td rowspan=1 colspan=1>Pepto-Bismol®</td><td rowspan=1 colspan=1>5% v/v</td></tr><tr><td rowspan=1 colspan=1>Imodium®</td><td rowspan=1 colspan=1>5% v/v</td></tr><tr><td rowspan=1 colspan=1>Kaopectate®</td><td rowspan=1 colspan=1>5% v/v</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>5% w/v</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>10 mg/g feces</td></tr></table>

f. Assay cut-off:

Specimens with values $\ge 1 2 8 ~ \mathrm { n g / m L }$ should show a positive result with the test. Results are reported as positive or negative.

2. Comparison studies:

a. Method comparison with predicate device: Correlation to the predicate was made by testing 375 samples.

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>LEUKO-TEST</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>LEUKOEZ VUE</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>153</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>215</td><td rowspan=1 colspan=1>222</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>375</td></tr></table>

$9 5 \%$ Confidence Intervals   
Positive percent agreement 93% (98/105) $8 6 \% - 9 7 \%$   
Negative percent agreement 80% (215/270) $74 \% - 8 4 \%$   
Overall agreement 83% (313/375) $8 0 \% - 8 6 \%$

b. Matrix comparison: Both assays test fecal specimens.

3. Clinical studies:

a. Clinical Sensitivity: Not done   
b. Clinical specificity: Not done   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: See assay cut-off

5. Expected values/Reference range: The expected result in the normal population is negative (below the assay cut-off). The prevalence of a positive test result using the LEUKO EZ VUE test in clinical investigations ranged between $2 7 \% - 5 3 \%$ . The prevalence will vary from

location to location and hospitals may experience rates lower or higher than those observed at the sites used in the studies. The prevalence will vary depending on the incidence of outbreaks due to various enteropathies.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.